On the front cover: Multiexpert Platform for the Identification of Hits Targeting Parasitic Enzymes

In the New Medicines for Trypanosomatidic Infections (NMTRypI) project funded by the EU and completed in January 2017, in which 13 partners participated, including the HITS Molecular and Cellular Modeling (MCM) and Scientific Databases and Visualization (SDBV) groups, novel anti-leishmanial and anti-trypanosomal hit compounds that inhibit pteridine reductase 1 (PTR1) were discovered. PTR1 is an enzyme of…